(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.64% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Merck & Co's revenue in 2026 is $65,768,000,000.On average, 31 Wall Street analysts forecast MRK's revenue for 2026 to be $166,594,596,440,580, with the lowest MRK revenue forecast at $159,688,967,376,240, and the highest MRK revenue forecast at $176,562,807,779,520. On average, 31 Wall Street analysts forecast MRK's revenue for 2027 to be $175,271,089,610,475, with the lowest MRK revenue forecast at $165,194,205,997,275, and the highest MRK revenue forecast at $187,395,457,663,710.
In 2028, MRK is forecast to generate $186,674,268,934,530 in revenue, with the lowest revenue forecast at $171,842,973,322,455 and the highest revenue forecast at $205,926,550,249,455.